Header Logo

Connection

ANG LI to Humans

Back to Details
This is a "connection" page, showing publications ANG LI has written about Humans.
ANG LI
Connection Strength
0.862
Humans
  1. Clonal hematopoiesis of indeterminate potential and incidence of venous thromboembolism in older adults. J Thromb Haemost. 2025 Jul; 23(7):2235-2241.
    View in: PubMed
    Score: 0.025
  2. Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system. J Thromb Haemost. 2025 May; 23(5):1539-1550.
    View in: PubMed
    Score: 0.024
  3. Transplant-associated TMA: the conundrum of diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):206-213.
    View in: PubMed
    Score: 0.024
  4. Circulating tumor DNA predicts venous thromboembolism in patients with cancers. J Thromb Haemost. 2025 Jan; 23(1):139-148.
    View in: PubMed
    Score: 0.024
  5. Racial and Ethnic Disparity for Cancer Mortality in General and Single-Payer Healthcare Systems in the United States. J Racial Ethn Health Disparities. 2025 Aug; 12(4):2646-2654.
    View in: PubMed
    Score: 0.023
  6. Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024 07; 99(7):1230-1239.
    View in: PubMed
    Score: 0.023
  7. Natural history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost. 2024 May; 22(5):1421-1432.
    View in: PubMed
    Score: 0.023
  8. Prospective Clinical and Biomarker Validation of the American Society for Transplantation and Cellular Therapy Consensus Definition for Transplantation-Associated Thrombotic Microangiopathy. Transplant Cell Ther. 2023 11; 29(11):685.e1-685.e7.
    View in: PubMed
    Score: 0.022
  9. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023 08; 98(8):1214-1222.
    View in: PubMed
    Score: 0.022
  10. External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center. Am J Hematol. 2023 07; 98(7):1052-1057.
    View in: PubMed
    Score: 0.022
  11. Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA). Thromb Res. 2023 05; 225:39-46.
    View in: PubMed
    Score: 0.021
  12. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023 06 01; 41(16):2926-2938.
    View in: PubMed
    Score: 0.021
  13. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. Am J Hematol. 2022 08; 97(8):1044-1054.
    View in: PubMed
    Score: 0.020
  14. External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol. 2022 06 01; 97(6):740-748.
    View in: PubMed
    Score: 0.020
  15. Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2022 05; 28(5):266.e1-266.e8.
    View in: PubMed
    Score: 0.020
  16. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. J Thromb Haemost. 2021 10; 19(10):2522-2532.
    View in: PubMed
    Score: 0.019
  17. Care Delivery in Cancer Patients With Asymptomatic COVID-19 Infection in a Tertiary, Safety-Net Hospital in Houston, Texas. Am J Clin Oncol. 2021 08 01; 44(8):409-412.
    View in: PubMed
    Score: 0.019
  18. Thrombotic Microangiopathy Increases the Risk of Chronic Kidney Disease but Not Overall Mortality in Long-term Transplant Survivors. Transplant Cell Ther. 2021 10; 27(10):864.e1-864.e5.
    View in: PubMed
    Score: 0.019
  19. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol. 2021 09 01; 96(9):1137-1146.
    View in: PubMed
    Score: 0.019
  20. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv. 2021 01 12; 5(1):167-175.
    View in: PubMed
    Score: 0.018
  21. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer. 2021 05 01; 127(9):1459-1468.
    View in: PubMed
    Score: 0.018
  22. Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. Transplant Cell Ther. 2021 04; 27(4):308.e1-308.e8.
    View in: PubMed
    Score: 0.018
  23. Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):82-84.
    View in: PubMed
    Score: 0.018
  24. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020 04 15; 126(8):1736-1748.
    View in: PubMed
    Score: 0.017
  25. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.
    View in: PubMed
    Score: 0.017
  26. The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Ann Hematol. 2020 Jan; 99(1):121-126.
    View in: PubMed
    Score: 0.017
  27. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019 12; 17(12):2141-2151.
    View in: PubMed
    Score: 0.017
  28. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2019 07 01; 17(7):840-847.
    View in: PubMed
    Score: 0.017
  29. Review: The quality of evidence is very low for periprocedural bridging in patients receiving VKA for VTE. Ann Intern Med. 2019 06 18; 170(12):JC64.
    View in: PubMed
    Score: 0.017
  30. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.
    View in: PubMed
    Score: 0.017
  31. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019 Aug; 180:37-42.
    View in: PubMed
    Score: 0.016
  32. Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. Biol Blood Marrow Transplant. 2019 03; 25(3):570-576.
    View in: PubMed
    Score: 0.016
  33. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 01; 173:158-163.
    View in: PubMed
    Score: 0.015
  34. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018 01; 16(1):164-169.
    View in: PubMed
    Score: 0.015
  35. Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency. Transfusion. 2017 09; 57(9):2151-2158.
    View in: PubMed
    Score: 0.014
  36. Use of Direct Oral Anticoagulants in Special Populations. Hematol Oncol Clin North Am. 2016 10; 30(5):1053-71.
    View in: PubMed
    Score: 0.014
  37. Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study. Transfusion. 2016 08; 56(8):2069-77.
    View in: PubMed
    Score: 0.013
  38. Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors. Br J Haematol. 2017 04; 177(1):142-144.
    View in: PubMed
    Score: 0.013
  39. Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System. Clin Lymphoma Myeloma Leuk. 2026 Jan; 26(1):e12-e20.e5.
    View in: PubMed
    Score: 0.006
  40. Immune Thrombotic Thrombocytopenic Purpura: A Review. JAMA. 2025 08 12; 334(6):517-529.
    View in: PubMed
    Score: 0.006
  41. Role and Use of Race in Artificial Intelligence and Machine Learning Models Related to Health. J Med Internet Res. 2025 Jul 31; 27:e73996.
    View in: PubMed
    Score: 0.006
  42. Development and validation of risk models for hospital-acquired bleeding in medical inpatients: the Medical Inpatients Thrombosis and Hemostasis (MITH) study. J Thromb Haemost. 2026 Feb; 24(2):418-430.
    View in: PubMed
    Score: 0.006
  43. Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review. Oncologist. 2025 Jun 04; 30(6).
    View in: PubMed
    Score: 0.006
  44. Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 07; 27(3):767-778.
    View in: PubMed
    Score: 0.006
  45. Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 Dec; 22(12):3521-3531.
    View in: PubMed
    Score: 0.006
  46. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Fail. 2024 Oct; 11(5):2742-2748.
    View in: PubMed
    Score: 0.006
  47. A Multi-Institutional Natural Language Processing Pipeline to Extract Performance Status From Electronic Health Records. Cancer Control. 2024 Jan-Dec; 31:10732748241279518.
    View in: PubMed
    Score: 0.006
  48. Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 02; 22(2):503-515.
    View in: PubMed
    Score: 0.006
  49. Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation. Thromb Res. 2023 09; 229:1-6.
    View in: PubMed
    Score: 0.005
  50. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open. 2023 06 01; 6(6):e2317945.
    View in: PubMed
    Score: 0.005
  51. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol. 2023 04; 201(2):280-284.
    View in: PubMed
    Score: 0.005
  52. Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. Cancer Res. 2022 01 15; 82(2):199-209.
    View in: PubMed
    Score: 0.005
  53. Differences in COVID-19-Related Testing and Healthcare Utilization by Race and Ethnicity in the Veterans Health Administration. J Racial Ethn Health Disparities. 2022 Apr; 9(2):519-526.
    View in: PubMed
    Score: 0.005
  54. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2022 Jan 02; 33(1):66-72.
    View in: PubMed
    Score: 0.005
  55. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 06; 4(3):464-472.
    View in: PubMed
    Score: 0.005
  56. The Effectiveness of Electronic Health Interventions for Promoting HIV-Preventive Behaviors Among Men Who Have Sex With Men: Meta-Analysis Based on an Integrative Framework of Design and Implementation Features. J Med Internet Res. 2020 05 25; 22(5):e15977.
    View in: PubMed
    Score: 0.004
  57. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020 06; 189(6):1171-1181.
    View in: PubMed
    Score: 0.004
  58. Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion. 2020 04; 60(4):841-846.
    View in: PubMed
    Score: 0.004
  59. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216.
    View in: PubMed
    Score: 0.004
  60. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019 10 22; 3(20):3062-3069.
    View in: PubMed
    Score: 0.004
  61. Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. Am Heart J. 2019 10; 216:117-124.
    View in: PubMed
    Score: 0.004
  62. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019 05 14; 3(9):1512-1518.
    View in: PubMed
    Score: 0.004
  63. Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies. Transfusion. 2019 05; 59(5):1773-1780.
    View in: PubMed
    Score: 0.004
  64. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017 07; 15(7):1322-1333.
    View in: PubMed
    Score: 0.004
  65. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr; 4(4):e157-e164.
    View in: PubMed
    Score: 0.004
  66. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol. 2015 Dec; 171(5):836-44.
    View in: PubMed
    Score: 0.003
  67. Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. Hematol Oncol. 2016 Sep; 34(3):147-53.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.